Skip to main content
SpringerLink
Log in

Immunoguiding, the Final Frontier in the Immunotherapy of Cancer

  • Chapter
  • First Online:
Cancer Immunotherapy Meets Oncology

  • 1900 Accesses

Abstract

T cells play an important role in cancer. This notion is strongly supported by an enormous number of trials on the clinical impact of tumor-infiltrating T cells and studies consequently showing that therapeutic interventions which are based on transfer, activation and expansion, or de-blocking of tumor-specific T cells, which have met with clinical success. To optimally profit from the flow of newly developed immune-based therapeutics aiming to reinforce the systemic and local tumor-specific T-cell response, it will be required to identify biomarkers that provide the rationale to use a particular therapy, that measure the effect of intervention, and that can predict the outcome of a therapeutic approach. Such biomarkers should first be identified and validated by (series of) harmonized immunological assays used for monitoring the immune system of patients and in a later phase may aid in guiding the choice and effect of therapy. In this chapter, the successes, new avenues, and challenges in immune monitoring of patients with cancer will be discussed in the context of current immunotherapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, Adema GJ, Figdor CG, Punt CJ, De Vries IJ (2012) Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 72(23):6102–6110. doi:10.1158/0008-5472.CAN-12-2479

    Article  PubMed  CAS  Google Scholar 

  • Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebaek E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72(7):1642–1650. doi:10.1158/0008-5472.CAN-11-2614

    Article  PubMed  CAS  Google Scholar 

  • Angell H, Galon J (2013) From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25(2):261–267. doi:10.1016/j.coi.2013.03.004

    Article  PubMed  CAS  Google Scholar 

  • Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69(21):8412–8419. doi:10.1158/0008-5472.CAN-09-0852

    Article  PubMed  CAS  Google Scholar 

  • Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM, Group C-CAW (2011) A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med 9:108. doi:10.1186/1479-5876-9-108

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Bidmon N, Attig S, Schroeder H, Rae R, Omoko T, Simon P, Kuhn A, Kreiter S, Sahin U, Gouttefangeas C, van der Burg SH, Britten CM (2014) Destigmatizing T-cell assays by continuous and tight control of performance (in press)

    Google Scholar 

  • Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22(2):215–222. doi:10.1016/j.coi.2010.02.006

    Article  PubMed  CAS  Google Scholar 

  • Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. doi:10.1016/j.immuni.2013.10.003

    Article  PubMed  CAS  Google Scholar 

  • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. doi:10.1056/NEJMoa1200694

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH (2008a) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57(3):289–302

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A (2008b) Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother 57(3):285–288

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P, Group HL-pMPPotC-CIAW (2009) Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 58(10):1701–1713. doi:10.1007/s00262-009-0681-z

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 60(1):15–22. doi:10.1007/s00262-010-0940-z

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM (2012) T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37(1):1–2. doi:10.1016/j.immuni.2012.07.010, S1074-7613(12)00291-9 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG (2011) Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71(4):1253–1262. doi:10.1158/0008-5472.CAN-10-2693

    Article  PubMed  CAS  Google Scholar 

  • Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJ, van der Burg SH, West M, Chan C (2013) Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol 9(7):e1003130. doi:10.1371/journal.pcbi.1003130

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949

    Article  PubMed  CAS  Google Scholar 

  • Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30(5):626–635. doi:10.1016/j.immuni.2009.05.002

    Article  PubMed  CAS  Google Scholar 

  • de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES (2013) Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer 133(12):2884–2894. doi:10.1002/ijc.28309

    Google Scholar 

  • de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23(24):5779–5787

    Article  PubMed  Google Scholar 

  • DeNardo DG, Brennan DJ, Rexhepaj E, Ruffel B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discover 1:54–67. doi:10.1158/2159-8274

    Article  CAS  Google Scholar 

  • Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, Vlodavsky I, Sommerfeldt N, Sinn HP, Kühnle MC, Schneeweiss A, Scharf A, Sohn C, Schirrmacher V, Moldenhauer G, Momburg F, Beckhove P (2009) Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 69(21):8420–8. doi:10.1158/0008-5472.CAN-09-1627

    Article  PubMed  CAS  Google Scholar 

  • Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–854. doi:10.1126/science.1076514

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA (2009) Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res 19(10):1817–1824. doi:10.1101/gr.092924.109

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. doi:10.1038/nrc3245

    Article  PubMed  CAS  Google Scholar 

  • Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–268. doi:10.1038/nri3175, nri3175 [pii]

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022. doi:10.1038/ni.2703

    Article  PubMed  CAS  Google Scholar 

  • Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11(3):215–233. doi:10.1038/nrd3626

    PubMed  CAS  Google Scholar 

  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964

    Article  PubMed  CAS  Google Scholar 

  • Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67(5):1883–1886

    Article  PubMed  CAS  Google Scholar 

  • Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O’Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D’Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012a) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205. doi:10.1186/1479-5876-10-205

    Article  PubMed Central  PubMed  Google Scholar 

  • Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA (2012b) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1. doi:10.1186/1479-5876-10-1

    Article  PubMed Central  PubMed  Google Scholar 

  • Galon J, Angell HK, Bedognetti D, Marincola FM (2013a) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39(1):11–26. doi:10.1016/j.immuni.2013.07.008

    Article  PubMed  CAS  Google Scholar 

  • Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D’Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F (2013b) Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol. doi:10.1002/path.4287

    Google Scholar 

  • Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12):953–964. doi:10.1038/nri1733

    Article  PubMed  CAS  Google Scholar 

  • Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59(5):663–674. doi:10.1007/s00262-009-0782-8

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6(7):520–526. doi:10.1038/nmeth.1345

    Article  PubMed  CAS  Google Scholar 

  • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. doi:10.1056/NEJMoa1305133

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013, S0092-8674(11)00127-9 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9(1):216. doi:10.1186/1479-5876-9-216, 1479-5876-9-216 [pii]

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466, NEJMoa1003466 [pii]

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102(18):1388–1397. doi:10.1093/jnci/djq310, djq310 [pii]

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A, Elispot Proficiency Panel of the CVCIAWG (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57(3):303–315

    Article  PubMed Central  PubMed  Google Scholar 

  • Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) “MIATA”-minimal information about T cell assays. Immunity 31(4):527–528. doi:10.1016/j.immuni.2009.09.007

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ (2008) Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-Cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14(7):2028–2035

    Article  PubMed  CAS  Google Scholar 

  • Kalos M (2010) An integrative paradigm to impart quality to correlative science. J Transl Med 8:26. doi:10.1186/1479-5876-8-26

    Article  PubMed Central  PubMed  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. doi:10.1056/NEJMoa1001294

    Article  PubMed  CAS  Google Scholar 

  • Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847. doi:10.1056/NEJMoa0810097, 361/19/1838 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Klinger M, Kong K, Moorhead M, Weng L, Zheng J, Faham M (2013) Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells. PLoS One 8(9):e74231. doi:10.1371/journal.pone.0074231

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 102(44):16013–16018. doi:10.1073/pnas.0500090102

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr, ASCO (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. doi:10.1200/JCO.2006.08.2644

    Article  PubMed  CAS  Google Scholar 

  • Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201(2):249–257. doi:10.1084/jem.20041378

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Maecker HT, McCoy JP Jr, Consortium FHI, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, Braun J, Korin Y, Reed E, Cho J, Hafler D, Davis M, Fathman CG, Robinson W, Denny T, Weinhold K, Desai B, Diamond B, Gregersen P, Di Meglio P, Nestle FO, Peakman M, Villanova F, Ferbas J, Field E, Kantor A, Kawabata T, Komocsar W, Lotze M, Nepom J, Ochs H, O’Lone R, Phippard D, Plevy S, Rich S, Roederer M, Rotrosen D, Yeh JH (2010) A model for harmonizing flow cytometry in clinical trials. Nat Immunol 11(11):975–978. doi:10.1038/ni1110-975

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM (2010) Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol Immunother 59(4):619–627. doi:10.1007/s00262-009-0814-4

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S (2013) A harmonized approach to intracellular cytokine staining gating: results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry Part A: J Int Soc Anal Cytol 83(8):728–738. doi:10.1002/cyto.a.22319

    Article  Google Scholar 

  • Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA (2013) Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 19(5):997–1008. doi:10.1158/1078-0432.CCR-12-2214

    Article  PubMed  CAS  Google Scholar 

  • Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8(5):351–360. doi:10.1038/nrc2373, nrc2373 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911. doi:10.1016/j.immuni.2009.03.019

    Article  PubMed  CAS  Google Scholar 

  • Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. doi:10.1200/JCO.2010.30.5425

    Article  PubMed  Google Scholar 

  • Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D (2004) Part I: Vaccines for solid tumours. Lancet Oncol 5(11):681–689

    Article  PubMed  CAS  Google Scholar 

  • Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S (2012) Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35(2):107–115. doi:10.1097/CJI.0b013e318242169f

    Article  PubMed  Google Scholar 

  • Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59(10):1489–1501. doi:10.1007/s00262-010-0875-4

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Moodie Z, Price L, Janetzki S, Britten CM (2012) Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 792:185–196. doi:10.1007/978-1-61779-325-7_15

    Article  PubMed  CAS  Google Scholar 

  • Murdoch DM, Staats JS, Weinhold KJ (2012) OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry. Cytometry Part A: J Int Soc Anal Cytol 81(4):281–283. doi:10.1002/cyto.a.22024

    Article  Google Scholar 

  • Nagtegaal ID, Quirke P, Schmoll HJ (2012) Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 9(2):119–123. doi:10.1038/nrclinonc.2011.157

    Google Scholar 

  • Newell EW, Klein LO, Yu W, Davis MM (2009) Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 6(7):497–499. doi:10.1038/nmeth.1344

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127(4):759–767. doi:10.1002/ijc.25429

    PubMed  CAS  Google Scholar 

  • Olson BM, McNeel DG (2013) Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol 3:109. doi:10.3389/fonc.2013.00109

    Article  PubMed Central  PubMed  Google Scholar 

  • Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666. doi:10.1056/NEJMoa051424

    Article  PubMed  CAS  Google Scholar 

  • Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944–5951. doi:10.1200/JCO.2008.19.6147

    Article  PubMed  CAS  Google Scholar 

  • Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH (2007) High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67(1):354–361

    Article  PubMed  CAS  Google Scholar 

  • Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770. doi:10.1158/1078-0432.CCR-12-1177

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Rakhmilevich AL, Alderson KL, Sondel PM (2012) T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol 31(4):267–278. doi:10.3109/08830185.2012.698337

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281. doi:10.1038/nri3191

    Article  PubMed  CAS  Google Scholar 

  • Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747–752. doi:10.1038/nm.3161

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8(10):577–585. doi:10.1038/nrclinonc.2011.116, nrclinonc.2011.116 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H (2013) The plasticity and stability of regulatory T cells. Nat Rev Immunol 13(6):461–467. doi:10.1038/nri3464

    Article  PubMed  CAS  Google Scholar 

  • Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC (2011) Tumor microenvironment is multifaceted. Cancer Metastasis Rev 30(1):13–25. doi:10.1007/s10555-011-9279-y

    Article  PubMed  Google Scholar 

  • Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62(1):137–147. doi:10.1007/s00262-012-1317-2

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH (2013) The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother 62(3):489–501. doi:10.1007/s00262-012-1351-0

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341(6151):1192–1198. doi:10.1126/science.1241145

    Article  PubMed  CAS  Google Scholar 

  • Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118(8):2254–2265. doi:10.1182/blood-2010-12-325753

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Thoren FB, Anderson H, Strannegard O (2013) Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunol Immunother 62(10):1547–1551. doi:10.1007/s00262-013-1458-y

    Article  PubMed  CAS  Google Scholar 

  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • van der Burg SH (2008) Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines 7(1):1–5

    Article  PubMed  Google Scholar 

  • van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R (2007) Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 104(29):12087–12092

    Article  PubMed Central  PubMed  Google Scholar 

  • van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A (2011) Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 3(108):108ps44. doi:10.1126/scitranslmed.3002785, 3/108/108ps44 [pii]

    PubMed  Google Scholar 

  • van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. doi:10.1200/JCO.2012.47.7521

    PubMed Central  PubMed  Google Scholar 

  • Verdegaal EM, Visser M, Ramwadhdoebe TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S (2011) Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother 60(7):953–963. doi:10.1007/s00262-011-1004-8

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261. doi:10.1038/nm.2883, nm.2883 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37(1):129–138. doi:10.1002/eji.200636435

    Article  PubMed  CAS  Google Scholar 

  • Warren RL, Freeman JD, Zeng T, Choe G, Munro S, Moore R, Webb JR, Holt RA (2011) Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. Genome Res 21(5):790–797. doi:10.1101/gr.115428.110

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, Pawelec G (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30(15):1835–1841. doi:10.1200/JCO.2011.40.2271

    Article  PubMed  CAS  Google Scholar 

  • Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365(9454):153–165. doi:10.1016/S0140-6736(05)17706-X

    Article  PubMed  Google Scholar 

  • Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 107(26):11895–11899. doi:10.1073/pnas.1006500107, 1006500107 [pii]

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH (2012) Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 61(7):967–978. doi:10.1007/s00262-012-1282-9

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133. doi:10.1056/NEJMoa1302369

    Article  PubMed  CAS  Google Scholar 

  • Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168(9):4272–4276

    Article  PubMed  CAS  Google Scholar 

  • Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108(40):16723–16728. doi:10.1073/pnas.1110814108

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21(3):281–285. doi:10.1016/j.coi.2009.05.007

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The CIP has been financially supported by a research grant from the Wallace Coulter Foundation (Florida, USA).

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Sjoerd H. van der Burg & Marij J. P. Welters

  2. Immatics Biotechnologies GmbH, Tuebingen, Germany

    Steffen Walter

  3. ZellNet Consulting, Inc., Fort Lee, NJ, USA

    Sylvia Janetzki

  4. Immunotherapy Development Center (IDC), TRON-Translational Oncology, University Medical Center, Johannes Gutenberg University, Mainz, Germany

    Cedrik Michael Britten

  5. BioNTech RNA Pharmaceuticals, Mainz, Germany

    Cedrik Michael Britten

  6. Laboratory of Integrative Cancer Immunology, INSERM, U872, Paris, France

    Jérôme Galon

  7. Department of Immunology, Institute for Cell Biology, Eberhard-Karls University, Tuebingen, Germany

    Cécile Gouttefangeas

Authors
  1. Sjoerd H. van der Burg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steffen Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia Janetzki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cedrik Michael Britten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jérôme Galon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marij J. P. Welters
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cécile Gouttefangeas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sjoerd H. van der Burg .

Editor information

Editors and Affiliations

  1. Immunotherapy Development Center (IDC), TRON-Translational Oncology University Medical Center, Johannes Gutenberg University, Mainz, Germany

    Cedrik Michael Britten

  2. Department of Immunotherapy Development Center, TRON-Translational Oncology University Medical Center, Johannes Gutenberg-University, Mainz, Germany

    Sebastian Kreiter

  3. Department of Immunotherapy Development Center, TRON-Translational Oncology University Medical Center, Johannes Gutenberg University, Mainz, Germany

    Mustafa Diken

  4. Department of Immunology, University of Tübingen, Tübingen, Germany

    Hans-Georg Rammensee

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

van der Burg, S.H. et al. (2014). Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. In: Britten, C., Kreiter, S., Diken, M., Rammensee, HG. (eds) Cancer Immunotherapy Meets Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-05104-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-05104-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-05103-1

  • Online ISBN: 978-3-319-05104-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation